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Abstract
Background A compact pre-filled auto-disable injection
(cPAD) presentation is being developed for the fully liquid
pentavalent DTP-HepB-Hib vaccine. A cost analysis (CA)
to compare this presentation with the presently used single-
dose vial (SDV) and multi-dose vial (MDV) was conducted
in Cambodia, Ghana, and Peru.
Methodology The CA included the development of an
excel-based costing model and considered the costs of
vaccine, safe injection equipment, procurement, storage,
transport and distribution, vaccine administration by health
staff, medical waste management, start-up activities, as
well as coverage, birth cohort, vaccine, and safe injection
equipment wastage rates. The outcome was the change in
cost per pentavalent fully immunized child (PFIC) for a
switch to cPAD. Field visits to health facilities, and inter-
views with key informants from immunization services and
regulatory authorities, were conducted to collect data and
to test the costing model in country context. Cost data were
also obtained from manufacturers, published price lists,
and author estimates. A sensitivity analysis (SA) was
conducted to explore possible variations in values of data
collected.
Results Based on vaccine price trends estimated for 2016,
cPAD is less costly in Ghana [incremental cost per PFIC:
$US-0.59 (-6.46 %)] than the current presentation (ten-
dose MDV) and in Peru (SDV): $US-0.89 (-7.14 %). In
Cambodia, cPAD is more costly than SDV: $US?0.33
(?3.90 %).
Discussion and Conclusion The most significant cost
item per PFIC is the vaccine (reflecting wastage rates) in all
presentations. The dominance of the vaccine price per dose
and, to a lesser extent, the wastage rates in the incremental
cost per PFIC show potential to simplify future analyses.
Other relevant considerations at country level for a change
of presentation include the potential for improved safety
with cPAD, planned introduction of other vaccines, envi-
ronmental and safety issues, and financial sustainability.
Key Points
The compact pre-filled auto-disable injection system
(cPAD), currently under development, is the less
costly presentation of the DTP-HepB-Hib vaccine in
Ghana and Peru as compared with the presently used
presentation, respectively multi-dose vial (MDV)
and single-dose vial (SDV). In Cambodia, the
currently used SDV would save costs as compared
with cPAD.
The largest cost item is the vaccine, reflecting
wastage rates.
At country level, a number of factors, such as
environmental and safety concerns, and financing
sustainability, may also be important when a change
in presentation is considered.
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Introduction
Immunizations against childhood communicable diseases
are among the most cost-effective public health interven-
tions [1]. Analyses of the costs and costeffectiveness of
introducing new vaccines and simplified delivery systems
are important to determine the level of resources required
to improve immunization programs, increase coverage, and
optimize the allocation of scarce resources [2].
Combination vaccines present advantages compared
with monovalent vaccines in terms of fewer injections for
children, ease of administration leading to reduced health
worker time, and possibly increased coverage [3]. Thus,
combining vaccines can reduce child mortality and help
reach the Millennium Development Goal 4 [4]. Techno-
logical improvements such as fully liquid combination
vaccines in a single injection have been developed to
rationalize vaccine delivery and to simplify supply and
administration of vaccines. The availability of vaccines
using easy-to-use technologies should strengthen immuni-
zation programs and contribute to increasing health service
performance [5]. Furthermore, simpler vaccine delivery
reduces the potential for handling errors, facilitates train-
ing, and enables vaccination programs to reach children in
remote areas [6].
UnijectTM is a compact pre-filled auto-disable injection
(cPAD) developed in the late 1980s by Becton Dickinson
in collaboration with the Program for Appropriate Tech-
nology in Health (PATH), with the objectives of reducing
transmission of infection caused by reusing and/or
improperly sterilizing syringes and needles, reducing vac-
cine wastage, improving access to immunization services,
and increasing coverage through simplifying the delivery
system [6]. cPAD devices have been used in Asia, Africa,
and Latin America since 1991 to administer vaccines
(tetanus toxoid, hepatitis B, and hepatitis A) [7, 8] and
drugs (cyclofem, oxytocin, etc.) [9, 10]. They potentially
present several key advantages over the single-dose vial
(SDV) and multi-dose vial (MDV), such as low wastage
rate, reduced waste management costs, very limited risk of
contamination, ease of use, and reduced administration
time [3, 8] (PATH 2011, pentavalent in Uniject market
research. Final report, unpublished) (PATH 2012, planning
for the introduction of Quinvaxem in Uniject. Health-
care waste management considerations. Draft report,
unpublished).
The decision to introduce a new vaccine and/or change
the format of presentation generally may be influenced by
(1) vaccine price, due to the lower price per dose of the
MDV compared with the SDV or cPAD such as UnijectTM,
(2) cold chain requirements, with the MDV occupying less
space per dose than the SDV or cPAD, (3) vaccine
wastage, because MDVs have significantly higher wastage
rates than SDVs and cPADs, (4) safety and contamination
risk, as with SDV and cPAD it is not necessary to draw
several doses from the same vial, (5) health staff time, as a
consequence of less time required to administer the vaccine
with a cPAD than with the other presentations, and (6)
medical waste because of the potential for reducing the
volume and weight of medical waste with cPAD, as glass
vials and syringes can be eliminated from the waste dis-
posal chain, and more cPAD than syringes can be disposed
of in one safety box.
The economic and programmatic consequences of
introducing a new delivery system in national immuniza-
tion programs are affected by the characteristics of these
programs, including their cost structure and efficiency level
[11]. A cost analysis (CA) of the various presentations of
the pentavalent1 vaccine was conducted in Ghana, Peru,
and Cambodia to provide evidence on the costs and ben-
efits of switching from the current pentavalent presentation
(SDV or MDV ten dose) to cPAD.
Methods
The main estimated outcome was the cost per pentavalent
fully immunized child (PFIC) for each presentation, where
the difference in cost per PFIC also included the cost of
switching (start-up cost) from the currently used presen-
tation to cPAD. The population targeted for the pentavalent
vaccine was children less than 1 year of age. The estimated
annual birth cohort was used in the calculations based on
the country population, growth rate, and natality rate.
Different time horizons were considered, depending on the
country’s respective immunization program planning pro-
cess: 5 years in Peru and Ghana and 8 years in Cambodia.
It was not an objective to compare costs between countries,
but rather to use and test the model in three different
country contexts. The countries were selected to represent
different continents, socio-economic conditions and current
vaccine presentations. The CA took the perspective of the
Ministry of Health (MoH) and considered the full costs of
each vaccine presentation, whatever the sources of
financing from point of entry into the country through to
delivery of the vaccine to children, as far as cost data were
available at different levels. In Ghana, the study adopted
the more restrictive perspective of the Expanded Program
on Immunization (EPI) rather than the wider MoH due to
the lack of readily available MoH detailed costing data for
the EPI. The MoH costing data did not differentiate by
program for such cost items as transport, storage, etc.
1 In the rest of this paper ‘‘pentavalent’’ is used to refer to the ‘‘DTP-
HepB-Hib vaccine’’.
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cPAD was compared with the currently used presentation:
SDV in Peru and Cambodia and MDV (ten doses) in
Ghana. A Microsoft Excel-based model was developed to
compute the costs and the cost per PFIC of administering
the pentavalent in three different possible presentations
(SDV, MDV-ten dose, and cPAD). The model was
designed as a simple tool requiring limited data and pro-
viding a simple cost-per-PFIC ratio (refer to Table 1 for all
the parameters considered) in order to be usable by the
immunization program managers. Where data were avail-
able, the models for each country were also populated to
allow comparison between all possible presentations, as in
Ghana with the SDV. We computed the incremental costs/
savings of using another format of the pentavalent vaccine
compared with the currently used presentation. This
approach assumes that the organizational infrastructure
already exists and the general administrative costs should
not be affected largely by the change in vaccine
presentation.
The following costs were estimated:
• vaccine and safe injection equipment plus their man-
agement costs.
• storage, transport, and distribution of the vaccines and
safe injection material.
• vaccine administration by health staff.
• medical waste management.
• start-up costs for the change and roll-out of a new
vaccine delivery system.
The vaccine prices for the cPAD and SDV utilized in the
CA were provided by the pentavalent manufacturer that
currently produces an SDV and that will launch cPAD in
2016; both prices are forecasts for that year. The vaccine
price used for the MDV is the lowest vaccine price con-
tracted with suppliers by UNICEF for 2016. The costs of
storage, transportation, and distribution of vaccines and
safe injection material were estimated based on available
cost data in each country and were otherwise estimated
based on the underlying assumption that the incremental
costs of each parameter compared with the base case would
reflect the relative importance of each parameter in relation
to the others. This assumption was necessary because
vaccine-specific and health system level (central, regional,
district, health facility) costing data were mostly not
available. The sensitivity analysis (SA) confirmed that this
assumption is valid over wide ranges for each of these
parameters. The start-up costs were depreciated on a linear
basis over their life span (estimated at 3 years for training
costs, which would need to be repeated due primarily to
staff turnovers and as a one-time investment for the other
items). The capital costs of increasing the cold chain
capacity in these countries were not included, as it was
assumed, based on discussions during the country visits,
that there was sufficient capacity available for introducing
the pentavalent vaccine in cPAD. All costs and outcomes
were discounted at 3 % per annum. Inflation was not
considered in the analysis, though the ranges used in the
SA were much greater than any reasonable inflation rate
might be. The results are expressed in $US, year 2013
values. The summary of the parameters used is detailed in
Table 1. The source of parameter values and how they
were estimated is detailed in Table 6 of the Electronic
Supplementary Material 1.
Due to the large uncertainty of the value of many of the
parameters, both univariate and probabilistic SAs were
performed [12] to test the robustness of the predictions, and
to identify the main contributors to uncertainty in the
predicted cost per PFIC. The univariate SA used low and
high absolute estimates of each parameter against the
background of best estimate values of the remaining
parameters to predict the incremental cost per PFIC. For
the probabilistic SA, parameters were sampled indepen-
dently and simultaneously from statistical distributions
(Table 2). Here, regression analysis was used to estimate
the contribution of each parameter to the uncertainty of the
incremental cost per PFIC. The contribution of a parameter
was measured as the difference in the predicted incre-
mental cost at the 2.5 and 97.5 %, and visualized in a
tornado diagram [13]. The analysis was based on a total of
1,000 model runs.
Results
Results of the Cost Analysis
The main results of the analysis in the three countries are
summarized in Tables 3 and 4 in terms of number of PFIC,
and absolute and incremental costs (total and per PFIC) of
cPAD compared with the currently used pentavalent
presentations.
The CA of the pentavalent vaccine shows that the least
costly presentation varies depending on the country context
(Table 1). In Ghana and Peru, cPAD is the least costly
presentation and leads to savings in terms of vaccines and
safe injection equipment procurement, medical waste
management, dry storage, and transportation. In Cambodia,
cPAD results in incremental costs due to the higher price
per dose of the new presentation. In all countries, the start-
up costs for training of health staff and monitoring and
evaluation activities represent a small share (below 2 %) of
the total costs of a new presentation such as cPAD.
Additional capital investment would not be required, as the
existing cold chain capacity in all countries was estimated
to be sufficient to accommodate the increased volume
required by the new cPAD presentation.
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Table 1 Specific parameter values used in the cost analysisa
Parameters in the model Cambodia Ghana Peru
Time horizon (years) 8 5 5
Population at start year (2011)b 14,962,591 26,009,711 30,135,875
Natality rate (2011)b 2.42 4.0 1.93
Growth rate of population for 2013–2017 (%)b 1.2 2.4 1.1
Immunization coverage of the pentavalent (%) 94 86 % 91
Number of pentavalent injections in children aged
0–1 year
3 3 3
Price of pentavalent in base case—FCA 2.26 (SDV) 1.95 (MDV-10) 2.40 (SDV)
Price of pentavalent in cPAD—FCA 2.41 2.41 2.55
Taxes on FCA for vaccine procured through UNICEF
(%)
15.5 4.5 handling charges; 8.0
freight insurance inspection
40.5
Procurement management costs in % of the cost of
vaccines and safe injection equipment
3.5 NA 0.1
Price of syringes—FCA 0.05 (0.5 ml AD) 0.04 (0.5 ml AD) 0.24 (1.0 ml AR)
Price of safety boxes—FCA 0.60 0.48 0.50
Wastage rate (%) of pentavalent in SDV 4 25 (MDV-10) 5
Wastage rate (%) of pentavalent in cPAD 2 2 2
Wastage rate (%) of syringes (auto-retractable, and AD)
and safety boxes (5 l)
10 10 10
Volume of the pentavalent in base-case format (cm3) 10.28 (SDV) 2.60 (MDV-10 dose) 10.28 (SDV)
Volume of the pentavalent in cPAD (cm3) 15.18 15.18 15.18
Volume of the syringes (cm3) 42.90 (0.5 ml AD) 42.90 (0.5 ml AD) 46.15 (1.0 ml AR)
Volume of the safety boxes (5 l)
Packed (cm3) 694 694 694
Unpacked (cm3) 5,840 5,840 5,840
Weight (g) of the safety boxes (5 l) 326.50 NA 326.50
Number of cPAD devices per safety box (5 l) 500 500 500
Number of syringes per safety box (5 l) 190 (0.5 ml AD) 190 (0.5 ml AD) 300 (1.0 ml AR)
Weight of the pentavalent vaccine in cPAD
(filled/empty cPAD)
4.14/1.17 g 4.14/1.17 g 4.14/1.17 g
Weight (g) of the pentavalent vaccine vial
(filled/empty vial)
5.44/2.65 (SDV) 8.87/3.87 (MDV-10) 5.44/2.65 (SDV)
Weight (g) of syringe secondary packaging/alone 4.80/2.90 (0.5 ml AD) 4.80/2.90 (0.5 ml AD) 4.50/2.80 (1.0 ml AR)
Transportation costs of vaccine from central to
provincial level
36/m3 50/m3 3/kg
Transportation costs—not refrigerated from central
to provincial level
36/m3 10/m3 1.5/kg
Refrigerated storage costs of vaccines (2–8 C)
at central level (per m3)
357 1,000 1,000
Dry storage costs at central level (per m3) 14 10 277
Labor costs for nurse at health center ($US/month) 110 1,035 682
Hours worked per month per health staff at health center NA 147 NA
Working days/year 236 220 220
Working hours/day 8 8 8
Staff time for one injection
With SDV/MDV 19.3 s (SDV) 15.3 s (MDV) 19.3 s (SDV)
With cPAD 7.5 s (cPAD) 7.5 s (cPAD) 7.5 s (cPAD)
Costs of contaminated waste collection and elimination 1/kg 5/m3 1.5/kg
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The estimated costs per PFIC for all presentations
shows that in all three countries, the most important cost
item of the cost per PFIC is the vaccine (including vac-
cine wastage) in any presentation, accounting for 85 % of
total cost in Peru and over 97 % in the two other coun-
tries, with the cPAD presentation leading to a higher
share of the total vaccine costs compared with SDV and
MDV (Table 4).
Results of the Sensitivity Analyses
The univariate SA shows that, under the assumption of the
values of the parameters in Table 1, the least costly pre-
sentation in almost all cases is the SDV in Cambodia, and
the cPAD in Ghana and Peru. This confirms the robustness
of the results of the evaluation. The probabilistic SA
(Fig. 1) illustrates the dominance of the respective vaccine
Table 2 Parameter value ranges and their distribution utilized for the sensitivity analysesa
Parameters Cambodia Ghana Peru
Price of the pentavalent in cPAD per dose 2.05–2.41–2.95 (triangular) 2.05–2.41–3.40 (triangular) 2.45–2.55–3.35 (triangular)






Coverage of cPAD and M/SDV presentation
(%)
92–94–95 (triangular) 80–86–97 (triangular) 90–91–95 (triangular)
Wastage rate of the pentavalent in cPAD (%) 1–2–3 (triangular) 1–2–3 (triangular) 1–2–3 (triangular)
Wastage rate of the pentavalent (%) (SDV) 1–4–5 (triangular) (MDV-10) 10–25–40
(triangular)
(SDV) 1–5–6 (triangular)
Wastage rate of the syringes and safety boxes
(%)
5–10–12 (triangular) 5–10–12 (triangular) 5–10–12 (triangular)
Dry storage costs at central level (per m3) 14–40 (uniform) 1–10–50 (triangular) 150–277–500 (triangular)








Refrigerated storage costs at central level
(per m3)
357–800 (uniform) 700–1,000–1,200 (triangular) 700–1,000–1,200
(triangular)




















cPAD compact prefilled auto-disable injection system, MDV multi-dose vial, SDV single-dose vial
a All costs are presented in $US. Triangular distributions are presented as lower—mode—upper
Table 1 continued
Parameters in the model Cambodia Ghana Peru












Discounting rate (%) 3 3 3
AD auto-disable, AR auto-retractable, cPAD compact pre-filled auto-disable injection system, FCA free carrier (incoterm), MDV multi-dose vial,
NA not applicable, SDV single-dose vial
a All costs are presented in $US
b The variables ‘population at start year’, ‘natality rate’, and ‘growth rate of population’ result in a different birth cohort per year over the time
horizon for each country
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Table 3 Estimated outcomes, total and incremental cost (total and per pentavalent fully immunized child) for the switch from current pre-
sentation to compact prefilled auto-disable injection systema
Outcomes/country Cambodia Ghana Peru
Period 8 years, 2013–2020 5 years, 2013–2017 5 years, 2013–2017
Birth cohort at start 362,095 1,040,388 581,622












Current presentation SDV MDV-10 dose SDV
Total costs of the current presentation 21,526,847 40,062,615 31,745,567
Total incremental costs in nominal value and % ?840,007 (?3.90 %) -2,590,026 (-6.46 %) -2,266,261 (-7.14 %)
Cost per PFIC of the current presentation 8.40 9.06 12.44
Incremental cost per PFIC in nominal value and % ?0.33 (?3.90 %) -0.59 (-6.46 %) -0.89 (-7.14 %)
MDV multi-dose vial, PFIC pentavalent fully immunized child, SDV single-dose vial
a All costs are presented in $US, year 2013 values
Table 4 Estimated absolute and incremental costs per pentavalent fully immunized child for the switch from current presentation to compact
prefilled auto-disable injection systema
Disaggregated costs
per PFIC












of cPAD vs. SDV
SDV cPAD Nominal
values
% MDV cPAD Nominal
values
% SDV cPAD Nominal
values
%
Cost per PFIC 8.40 8.73 0.33 ?3.90 9.06 8.47 -0.59 -6.46 12.44 11.56 -0.89 -7.14




8.16 8.52 0.36 ?4.46 8.78 8.30 -0.48 -5.42 10.65 10.97 0.32 ?3.00
Procurement management
costs of vaccinesb




0.19 0.00 -0.19 -97.61 0.18 0.01 -0.18 -95.84 1.13 0.00 -1.13 -99.59
Procurement management
costs of safe injection
equipment
0.00 0.00 0.00 -97.61 0.00 0.00 0.00 0.00 0.04 0.00 -0.04 -99.59
Start-up costs 0.00 0.17 0.17 -100.00 0.00 0.08 0.08 0.00 0.00 0.07 0.07 -100.00
Staff cost total 0.01 0.00 0.00 -61.14 0.09 0.04 -0.04 -50.98 0.07 0.03 -0.05 -61.14
Total cold chain cost 0.01 0.02 0.01 ?44.65 0.01 0.05 0.04 ?346.82 0.03 0.05 0.01 ?43.15
Total dry storage cost 0.00 0.00 0.00 -97.02 0.00 0.00 -0.00 -97.70 0.04 0.00 -0.04 -97.14
Total transportation cost
refrigerated
0.00 0.00 0.00 ?44.65 0.00 0.00 0.00 ?346.82 0.05 0.04 -0.01 -26.23
Total transportation cost
dry
0.01 0.00 -0.01 -97.02 0.00 0.00 -0.00 -97.70 0.03 0.00 -0.02 -88.40
Disposal cost 0.02 0.01 -0.01 -63.80 0.00 0.00 -0.00 -65.10 0.02 0.01 -0.01 -56.58
cPAD compact prefilled auto-disable injection system, MDV multi-dose vial, PFIC pentavalent fully immunized child, SDV single-dose vial
a All costs are presented in $US, year 2013 values
b The vaccine prices used are expected prices in 2016 comparable to major procurement prices
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purchase prices (cPAD and SDV, MDV) in the uncertainty
in predicting the incremental cost per PFIC in all three
countries. Some other parameters (i.e. wastage rate of the
pentavalent in SDV in Cambodia and Peru, start-up costs in
Cambodia, and wastage rate of the pentavalent in cPAD in
Ghana, respectively) add to the uncertainty to a lesser
extent. In Ghana, the wastage rates of MDV-ten doses are
the second-most important cause of uncertainty.
In all three countries, varying the discount rate (0, 7 %)
did not cause any change in the least costly presentation.
Other Findings
Outcomes pertaining to storage, transport, and medical
waste of the different presentations of the pentavalent
vaccine show that the cPAD would lead to an incremental
cold chain requirement as compared with the SDV and
MDV. In Ghana, the cPAD would cumulatively require an
additional 169.3 m3 (?346.8 %) (average per year 33.9 m3
based on the additional volume of the cPAD compared
with the base-case MDV-ten dose) of cold chain over
5 years, while in Cambodia and Peru the incremental
required cold chain capacity would be 40.7 m3 (?44.6 %)
over 8 years (average per year 5.1 m3 based on the addi-
tional volume of the cPAD compared with the base-case
SDV) and 37.9 m3 (?43.1 %) (average per year 7.6 m3
based on the additional volume of the cPAD compared
with the base-case SDV) over 5 years, respectively
(Table 5). These incremental volumes apply to the whole
system and were not broken down per level. On the other
hand, cPAD would save dry storage volume and drastically
reduce medical waste generated. For instance, cPAD pre-
sentation would allow saving 4,406,257 doses (or 187,744
glass vials) and 15,645,407 syringes, representing a total of
347.85 m3 of medical waste in Ghana over 5 years, by
removing glass vials from the medical waste production.
Discussion
To our knowledge, this is the first CA comparing the cPAD
with the SDV and MDV-ten dose presentations. It shows
that, in all three countries, the most important cost item of
the cost per PFIC is the pentavalent vaccine in any pre-
sentation (including vaccine wastage) and that the cPAD
Fig. 1 Contribution of input values on the uncertainty of the
predicted incremental cost per pentavalent fully immunized child of
compact prefilled auto-disable injection system versus single-dose
vial in Cambodia and Peru, ten-dose multi-dose vial in Ghana. cPAD
compact prefilled auto-disable injection system, MDV multi-dose vial,
PFIC pentavalent fully immunized child, SDV single-dose vial.
Program used: R, plots are in wmf format
b
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can be less costly than the other presentations. Amongst the
large number of economic evaluations of vaccines, few
deal with the pentavalent vaccine; the most recent usually
consider Hib vaccine to be a cost-effective intervention
[14]. Specific parameters considered when comparing
vaccine presentations are start-up costs [15], medical waste
management [16], required health staff time for vaccine
administration [17], in addition to other commonly con-
sidered parameters (price of vaccine and safe injection
equipment, wastage rates, and cold chain requirements).
Other factors would influence the decision to switch to
the cPAD for the pentavalent vaccine. Such a switch leads
to substantial reductions in safe injection equipment
required (no syringes are needed and fewer safety boxes
are required), translating into reduced dry storage and
transportation volume. Logistical issues for immunization
programs relate notably to the volume per dose of the
vaccine, which impacts on the required cold chain capacity
for both distribution and storage because the volume of a
unit dose of a vaccine in an MDV is smaller than in an
SDV, which is in its turn smaller than in a pre-filled AD
device [3]. Our study highlights the expected reduction in
dry storage space and the greater requirements in terms of
cold chain capacity.
In addition, the cPAD considerably reduces the volume
of medical waste generated and eliminates glass vials and
syringes from the waste stream. The vial size impacts on
the volume of waste produced; SDVs generate more waste
per dose than MDVs, and cPADs generate significantly less
waste than SDVs and MDVs [3]. This aspect is critical
in situations where not only health staff is exposed to
contaminated waste but also communities because of fre-
quent sub-standard waste management processes. Our
findings show that such a reduction in medical waste can be
expected in the three countries.
Other possible advantages of using the cPAD include a
reduced number of needle stick injuries (not explored
here). Also, vaccine withdrawal from a vial is not required
with the cPAD, leading to reduced vial contamination and
resulting disease transmission. It is commonly considered
that SDVs are safer than MDVs [18] because of a reduced
risk of cross contamination and risk of blood-borne disease
transmission. In addition, the cPAD and AD syringes used
with SDVs and MDVs offset the risks of reusing syringes.
Where a high investment in cold chain capacity is
required, this could have a substantial effect on the cost
structure of a switch to cPAD and the incremental cost or
savings.
Lower-dose vials may reduce missed opportunities for
immunization because health personnel have been shown
to be reluctant to open a new MDV with a limited number
of patients [19, 20]. This attitude leads to a reduction in the
coverage of immunization services in outreach sessions.
Gaps in the existing body of literature exist concerning the
impact of cPAD as compared with other delivery systems
on immunization service coverage in clinical settings.
It has been recommended that countries consider having
a mix of different presentations of the same vaccine,
depending on the nature of the immunization session (small
or large throughput of patients) and of the immunization
strategies (fixed or outreach) [3, 21–23]. For instance, for
expensive vaccines, SDVs would be more appropriate in
small sessions while MDVs would be more suitable in
larger sessions. These recommendations are based on the
price of vaccines, wastage rates of vaccine presentation,
cold chain requirements, and disposal. Some break-even
Table 5 Incremental predictions (total and per pentavalent fully
immunized child) of storage and medical waste generated by compact
prefilled auto-disable injection system as compared with single-dose
vials in Cambodia and Peru and versus multi-dose vials in Ghana over
the respective time horizon







Total incremental predictions over the considered period
Dry storage volume, m3 (%) -427.33 (-97.02) -706.15 (-97.02) -424.59 (-97.14)
Cold chain volume, m3 (%) ?40.74 (?44.65) ?169.30 (?346.82) ?37.90 (?43.15)
Medical waste volume, m3 (%) -210.51 (-65.10) -347.85 (-65.10) -87.59 (-44.90)
Medical waste weight, tons (%) -29.05 (-63.80) -48.01 (-63.80) -20.46 (-56.58)
Disaggregated incremental predictions per PFIC
Dry storage volume (cm3) -150.45 -150.45 -159.92
Cold chain volume (cm3) ?14.34 ?36.07 ?14.01
Medical waste volume (cm3) -74.11 -74.11 -32.37
Medical waste weight (g) -10.23 -10.23 -7.56
MDV multi-dose vial, PFIC pentavalent fully immunized child, SDV single-dose vial
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CAs have been shown to be very country specific [21, 23].
However, the impact of different presentations of the same
vaccine on logistics management has to be weighed
carefully.
Perception studies showed a globally high acceptability
of cPAD (specifically UnijectTM) by health staff, who
preferred it to syringes and vials due to practicality, dose
accuracy, reduced contaminated waste, time savings, and
increased patients’ acceptability (PATH 2011, pentavalent
in Uniject market research. Final report, unpublished) [9].
Disadvantages of cPAD were rarely reported and were
related to possible needle stick injuries, increased refrig-
erated volume, and the inability to practice aspiration [10,
24, 25] (PATH 2011, pentavalent in Uniject market
research. Final report, unpublished). High acceptance by
patients was associated with less fear of injection with the
device and perception of higher safety [6, 10, 24]. Most
perception studies were conducted with medicines other
than vaccines, in outreach settings, and with lay health
workers. Several studies reported the potential of cPAD to
increase coverage, notably for HepB immunization in
outreach interventions using unrefrigerated vaccine [6, 7,
26].
The likeliness of switching to cPAD is closely linked
to its financing (including sustainability) and its impact
on the whole EPI budget. While the Peruvian Govern-
ment finances the pentavalent vaccine entirely, the
Ghanaian and Cambodian Governments still depend at
least partially upon donors (in both countries, the GAVI
Alliance has been funding part of the introduction of the
pentavalent vaccine and safe injection equipment and has
provided vaccine introduction grants to cover start-up
costs). A budget impact analysis (BIA) would usefully
complement this CA, as it is increasingly being recom-
mended [27] and because the immunization schedules of
individual countries change with the introduction of new
vaccines. For instance, Cambodia has planned the
introduction of the pneumococcal vaccine in 2015 and
Peru introduced the inactivated polio vaccine (IPV) in
2013.
This CA of the pentavalent has a number of limitations.
Every model is a simplification of reality and therefore
cannot capture all possible factors, events, or outcomes. In
addition, the CA is based on a model developed for this
study which, requiring a limited amount of data, was
intentionally simple in order to be usable by the immuni-
zation program managers. The model does not account for
possible change over time in fertility and population
growth rate, which will affect the size of the birth cohort
and consequently the number of doses required. Further,
vaccine coverage over time is static. As not all parameter
data were easily available, the cost of transportation and
storage is only reflected for national to provincial or
regional level in all three countries. Thus, the study
underestimates the benefits of SDV and MDV compared
with cPAD in terms of cost of refrigerated storage and
distribution of vaccines below the intermediary level. The
benefits of storage and transportation of safe injection
equipment associated with cPAD compared with other
presentations have also not been reflected below the
intermediary level and therefore savings associated with
cPAD are underestimated. Also, values for the various
parameters may vary in accuracy and reliability as the data
required for our model were collected from a variety of
sources, including records and interviews at various levels.
Nevertheless, as shown by both types of SA performed,
the main influential factor on this CA is the price of the
vaccine in all countries for which precise indications—
estimates for 2016 comparable with major procurement
prices—were obtained from the manufacturer and the
UNICEF published pentavalent price list. These findings
imply that the framework of analysis presented here is
applicable for other types of vaccines.
Conclusion
This study shows, based on vaccine price projections for
2016, that the introduction of the pentavalent in the cPAD
is less costly in Peru and Ghana than the current vaccine
presentation (SDV and MDV-ten doses, respectively),
while in Cambodia the current SDV presentation remains
less costly. One parameter that is not included in the
evaluation, but which may be significant in countries where
the cold chain capacity is more limited, is the capital cost
of its expansion to accommodate the higher volume per
PFIC associated with cPAD.
Furthermore, this study provides a CA model for ana-
lyzing a change in vaccine presentations that can be
applied to various settings and vaccines other than the
pentavalent. The model and the SA illustrate the domi-
nance of the vaccine price per presentation, adjusted to
reflect wastage rates as the main cost item of the CA. This
indicates the potential to simplify future analyses by
focusing only on cost and wastage of vaccine and safe
injection materials. The difficulty of obtaining reliable
costing data for many of these apparently less important
parameters could thus be avoided.
However, for decision making and policy dialogue at
country level, several other factors maybe equally as
important as the incremental costs of the vaccine when
considering shifting to a new presentation such as cPAD.
These are mainly related to easier logistics management,
environmental aspects such as reduced waste generated,
potential for increased safety, financing sustainability, and
budget impact.
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